If your email program has trouble displaying this email, view it as a web page. Announcement courtesy of the National Cancer Institute's (NCI) Center for Cancer Research (CCR) at the National Institutes of Health (NIH) | https://ccr.cancer.gov 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology Registration Open! Date:               September 15-16, 2022 Location:        Building 10, Lipsett Amphitheater Host:               CCR Center of Excellence in Immunology For more information on the program, as well as online registration, please go to: https://go.cancer.gov/Gpp47Nn   Organizers: Steven Rosenberg, M.D., Ph.D., Center for Cancer Research, NCI Claudia Palena, Ph.D., Center for Cancer Research, NCI James Gulley, M.D., Ph.D., Center for Cancer Research, NCI Sessions and Speakers CAR T-Cell Based Immunotherapies. Michel Sadelain, James Kochenderfer, Katy Rezvani, Cameron Turtle, Nirali Shah Cell Therapy for Solid Epithelial Cancers. Steven Rosenberg, Carl June, Christian Hinrichs, Stefanie Mandl, Philip Greenberg, Crystal Mackall Principles of Checkpoint Modulators. James Allison, Arlene Sharpe, Padmanee Sharma Clinical Applications of Checkpoint Modulators. Suzanne Topalian, Jedd Wolchok, James Gulley Microbiomes and Immunotherapy. Thomas Gajewski, Jennifer Wargo, Laurence Zitvogel Factors Influencing the Success of Immunotherapy. Nir Hacohen, Antoni Ribas, Robert Vonderheide, Claudia Palena Innovative Approaches to Immunotherapy.  Sofia Gameiro, Rosandra Kaplan, Christoph Rader, Peter Choyke Important Dates: Registration Deadline is September 1, 2022 Abstract Submission Deadline is August 19, 2022 ALL NIH EMPLOYEES WILL BE VIRTUAL ATTENDEES. For conference-related questions, please contact ccrconferences@mail.nih.gov. This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA